KR20100126453A - 조합 항암제 - Google Patents

조합 항암제 Download PDF

Info

Publication number
KR20100126453A
KR20100126453A KR1020107021665A KR20107021665A KR20100126453A KR 20100126453 A KR20100126453 A KR 20100126453A KR 1020107021665 A KR1020107021665 A KR 1020107021665A KR 20107021665 A KR20107021665 A KR 20107021665A KR 20100126453 A KR20100126453 A KR 20100126453A
Authority
KR
South Korea
Prior art keywords
administered
lucantone
lucanton
anti metabolites
metabolites
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020107021665A
Other languages
English (en)
Korean (ko)
Inventor
구루 레디
루이지 레나즈
Original Assignee
스펙트럼 파마슈티컬즈 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스펙트럼 파마슈티컬즈 인크 filed Critical 스펙트럼 파마슈티컬즈 인크
Publication of KR20100126453A publication Critical patent/KR20100126453A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020107021665A 2008-02-29 2009-02-20 조합 항암제 Abandoned KR20100126453A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3283108P 2008-02-29 2008-02-29
US61/032,831 2008-02-29

Publications (1)

Publication Number Publication Date
KR20100126453A true KR20100126453A (ko) 2010-12-01

Family

ID=40566524

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107021665A Abandoned KR20100126453A (ko) 2008-02-29 2009-02-20 조합 항암제

Country Status (13)

Country Link
US (1) US20090221615A1 (enExample)
EP (1) EP2257285A1 (enExample)
JP (1) JP5590560B2 (enExample)
KR (1) KR20100126453A (enExample)
CN (1) CN102014895A (enExample)
AU (1) AU2009219464B2 (enExample)
BR (1) BRPI0908398A2 (enExample)
CA (1) CA2717100A1 (enExample)
IL (1) IL207859A (enExample)
MX (1) MX2010009502A (enExample)
RU (1) RU2516027C2 (enExample)
WO (1) WO2009108573A1 (enExample)
ZA (1) ZA201006123B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6182313B2 (ja) * 2010-03-08 2017-08-16 スペクトラム ファーマシューティカルズ インコーポレイテッド 癌治療のためのチオキサントンをベースとしたオートファジー阻害剤療法
EP2425830A1 (en) 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
WO2023114245A2 (en) * 2021-12-14 2023-06-22 Radin Daniel Pierce Compositions and methods for treating cancers of the central nervous system (cns), including glioblastoma and chemoresistant cns tumors, and related compositions and methods for inhibiting and eliminating cns cancer stem cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ504108A (en) * 1997-09-26 2002-06-28 Noven Pharma Bioadhesive compositions comprising a polyvinylpyrrolidone polymer and methods for topical administration of active agents
US6391911B1 (en) * 1999-02-26 2002-05-21 Robert E. Bases Coadministration of lucanthone and radiation for treatment of cancer
EP1971338B8 (en) * 2005-12-22 2011-09-21 AstraZeneca AB Combination of zd6474 and pemetrexed
JP2009520787A (ja) * 2005-12-22 2009-05-28 アストラゼネカ アクチボラグ Ａｚｄ２１７１およびペメトレキセドの組み合わせ

Also Published As

Publication number Publication date
WO2009108573A1 (en) 2009-09-03
BRPI0908398A2 (pt) 2015-08-11
CN102014895A (zh) 2011-04-13
IL207859A (en) 2015-09-24
RU2010139840A (ru) 2012-04-10
RU2516027C2 (ru) 2014-05-20
MX2010009502A (es) 2010-11-10
ZA201006123B (en) 2011-05-25
IL207859A0 (en) 2010-12-30
CA2717100A1 (en) 2009-09-03
AU2009219464A1 (en) 2009-09-03
EP2257285A1 (en) 2010-12-08
JP5590560B2 (ja) 2014-09-17
US20090221615A1 (en) 2009-09-03
AU2009219464B2 (en) 2015-04-09
JP2011513315A (ja) 2011-04-28

Similar Documents

Publication Publication Date Title
JP2014012721A (ja) ｍＴＯＲ阻害剤投与によるがん患者の治療
US20070281040A1 (en) Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents
US6391911B1 (en) Coadministration of lucanthone and radiation for treatment of cancer
JP5642892B2 (ja) 多形膠芽腫の治療のためのマシテンタンを含有する組み合わせ剤
JP5590560B2 (ja) 組合せ抗がん剤
US20130101680A1 (en) Radiotherapy enhancer
JP2025163103A (ja) 放射線および／または抗がん治療補助療法としてアデノシン二リン酸リボースの活用
US20230038138A1 (en) Combination therapy for treating cancer
CN111939165B (zh) 非天然人参皂苷3β-O-Glc-DM在制备预防或治疗胶质母细胞瘤药物中的应用
CA3245251A1 (en) TREATMENT METHOD COMPRISING KRAS G12C INHIBITORS AND SHP2 INHIBITORS
US20220395575A1 (en) Combination therapy with protein kinase b activation inhibitor to treat cancer
CN115190800A (zh) 一种brd4抑制剂的用途
MXPA06014477A (es) Agente antitumor, fortificador de efecto antitumor y metodo de terapia para cancer.
CN111821302A (zh) 用于联合治疗软骨肉瘤的喹啉类化合物
CN107137406B (zh) 一种Hedgehog信号通路抑制剂在制备治疗EGFR过度表达的癌症的药物中的用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100928

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140218

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150601

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20151209

PC1904 Unpaid initial registration fee